Coherus Files Two More Petitions for IPR of Abbvie’s ‘619 Humira Patent
By EsqSocial Corporation 06/03/17
Coherus Biosciences has filed two petitions for inter partes review of Abbvie’s U.S. Patent 9,085,619. (IPR2017-01008 and IPR2017-01009). Coherus recently filed four other petitions for inter partes review of the ‘619 patent, as we’ve reported....
By: Goodwin